Kornimate/medical-research-clean huggingface dataset:
n-acetylcysteine as an adjuvant therapy in critically ill covid-19 patients:

Conditions: COVID-19 Pneumonia

Summary: in this study, we retrospectively will investigate safety and efficacy of nac dose given in paracetamol toxicity as an adjuvant therapy in critically ill covid-19 patients with acute respiratory distress and determine whether nac in high doses can avoid respiratory failure in patients with covid-19.

type of study:retrospective observational cohort study. study setting: ain shams university hospitals . study period: from december 2020 to february 2022 study population:patients aged 18 years or older of both genders diagnosed with confirmed critically ill covid-19 . this is a retrospective observational study in which all cases will be collected from icu of ain shams university hospitals during covid-19 outbreak. all data will be extracted from clinical records. all patients initially admitted to icu with spo2 less than 94 % will be included between december 2020 to february 2022. infection with covid-19 was confirmed by pcr. all patients received standard care, according to the institutional protocol. laboratory and radiological investigations demographic, clinical, laboratory, management, and outcome data will be obtained from the medical records. routine laboratory tests were done for all patients, including cbc, c-reactive protein, renal profile, coagulation profile, liver profile, lactate, electrolytes, procalcitonin, ferritin and d-dimer.infection with covid-19 was confirmed by reverse transcriptase-polymerase chain reaction (rt-pcr) assay of nasopharyngeal swab. chest computed tomography (ct) was also done for all patients.

Eligibility criteria:
inclusion criteria: * oxyhemoglobin saturation (sao2) of less than 94% while breathing ambient air exclusion criteria: * need for immediate mechanical ventilation on admission, known allergy or hypersensitivity to nac, end stage renal and liver diseases, heart failure and pregnancy.
clinical trial to evaluate the efficacy and safety of 'dw1601' in acute bronchitis

Conditions: Acute Bronchitis

Summary: a multicenter, randomized, double-blind, parallel, active-controlled, superiority, phase iii clinical trial to evaluate the efficacy and safety of dw1601 compared to dw16011 and dw16012 for acute bronchitis


Eligibility criteria:
inclusion criteria: * both gender, 19 years ≤ age ≤ 80 years * bronchitis severity score\* ≥ 5point at visit 2 (randomized visit) * acute bronchitis within 48hr based on visit 2 (randomized visit) * those who can comply with the requirements of clinical trials * written consent voluntarily to participate in this clinical trial exclusion criteria: * patients who investigators determines to severe respiratory disease that would interfere with study assessment * patients with systemic infections requiring systemic antibiotic therapy * patient with hemostatic disorder
a pilot trial to test the feasibility of prolonged fasting and ketogenic diet in relapsing-remitting multiple sclerosis

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: it is well accepted that nutrition as an environmental factor is involved in the pathogenesis of multiple sclerosis. but is there a role for prolonged fasting and ketogenic low glycemic load treatment to alter the course of multiple sclerosis (ms)? the investigators think yes there is. primarily the investigators want to detect if these diets are feasible for ms patients. therefore the investigators examine the impact of this dietary intervention on the health related quality of life for individuals after 7 days, 3 months and 6 months in compare to baseline. secondarily the investigators focus on endocrinological and immunological changes after 7 days, 3 months and 6 months in compare to baseline.

in this controlled randomised pilot study the patients are allocated to 1. a ketogenic low glycemic load treatment from the outset of the study for 24 weeks or 2. enhance their regular diet with an initial 7-day fasting followed by a mediterranean diet pattern until the study end or 3. stay on their regular diet (control group) from the outset of the study for 24 weeks. the investigators will then assess the differences between the groups.

Eligibility criteria:
inclusion criteria: * relapsing remitting ms * stable immunomodulatory treatment or no treatment at least 6 months prior to inclusion * expanded disability status scale \< 7 * body mass index (bmi) \> or = 18,5 or bmi \> or = 45 with no risk factors * not pregnant or breast-feeding * no serious mental health illness such as dementia or schizophrenia; * no use of a weight loss therapy in the month prior to screening. exclusion criteria: * start or changes if immunomodulatory treatment \< 7 months prior to screening * spms or ppms * relapse or corticosteroid use \< 30 days prior to screening * diabetes or any metabolic defects * bulimia * anorexia * drug abuse

Keywords: multiple sclerosis diet prolonged fasting caloric restriction ketogenic low glycemic load treatment health related quality of life ketogenic diet neurodegeneration neuroinflammation
gastric cancer metastasized to the central nervous system (cns)

Conditions: Gastric Cancer

Summary: descriptive registry to investigate frequency of her-2 positive gastric cancer involving cns. exploration of additional prognostic factors for brain involvement from gastric cancer.

her2 status e-cadherin status

Eligibility criteria:
inclusion criteria: * in order to be eligible for the study, the diagnosis of gastric cancer and/or lower esophageal cancer must be confirmed histologically. cns involvement must be confirmed either via independent neuroradiological and/or positive csf cytology. exclusion criteria: * patients whose diagnosis is not confirmed upon pathological review or where the cns involvement cannot be confirmed after neuroradiological review will be excluded from this study.

Keywords: central nervous system pathological markers
role of anti-inflammatory agents in patients with schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder; Psychosis Not Otherwise Specified; Schizophreniform Disorder

Summary: there is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. cox-2 inhibitors have been tested in preliminary clinical trials for schizophrenia and depression, showing favourable effects compared to placebo (muller and schwarz et al 2009). statins were introduced as cholesterol-lowering agents but have found much wider usage. they are anti-inflammatory agents and thus similar to the cox-2 inhibitors, which have shown some ability as adjuncts to improve the symptoms of schizophrenia in preliminary studies. the statins are also known to decrease c-reactive protein (crp), which has been shown in an smri-funded study to be elevated in a study of individuals with schizophrenia. fan et al (2007) demonstrated in a small study in patients with schizophrenia that higher than normal levels of crp (\>0.50 mg/dl) was associated with marked negative symptoms and higher total panss scores. ondansetron is a serotonin (5-ht3) receptor antagonist that is generic and widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer. gsk did a small study on it as an antipsychotic in the 1980s. since then, several small studies have suggested that it is effective as an adjunct drug in improving the symptoms of schizophrenia. statins are widely used in schizophrenia sufferers, particularly those taking second generation antipsychotics, to treat hypercholesterolemia. both drugs are well tolerated and their side effect profiles well understood. we propose to conduct a feasibility study in patients with chronic schizophrenia to explore the adjunct use of simvastatin and ondansetron on positive, negative and general psychopathology in comparisons to treatment as usual (tau) over a 12 week period.


Eligibility criteria:
inclusion criteria: 1. diagnostic and statistical manual-iv (dsm-iv) diagnosis of schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder 2. competent and willing to give informed consent 3. stable on medication 4 weeks prior to baseline 4. able to take oral medication and likely to complete the required evaluations 5. female participants of child bearing age must be willing to use adequate contraceptives for the duration of the study, and, willing to have a pregnancy test pre treatment and at ten weekly intervals while on study medication. exclusion criteria: 1. relevant medical illness \[renal and hepatic\] in the opinion of the investigators 2. history of high alcohol intake 3. any change of psychotropic medications within the previous six weeks 4. diagnosis of substance abuse (except nicotine or caffeine) or dependence within the last three months according to dsm-iv criteria 5. pregnant or breast-feeding.

Keywords: anti inflammatory schizophrenia simvastatin ondansetron
international prospective study on morphine-induced adverse drug reactions in emergency departments.

Conditions: Emergencies

Summary: morphine is the gold standard for treatment of severe acute pain but it has a number of adverse effects. no study has so far managed to identify the morphine-induced adverse drug reactions. the primary objective of this study is to determine predictive factors of morphine-induced adverse drug reaction when it is used in emergency departments.

we want to study a large cohort of morphine-induced adverse drug reactions patients, the consequences for patients, mainly in terms of severity, and predictive criteria. this will allow us to identify some patients most at risk of morphine-induced adverse drug reactions, and thus to adapt morphine titration and monitoring of these patients. leading to a better understanding and a better prediction of adverse effects in patients, it is possible that part of the "opiophobia" which persists in emergency services disappear. finally, it is toward a better security but also a better efficiency in the management of pain patients in emergencies that leads this study. the secondary objectives are: to determine the frequency and severity of adverse events related to morphine. to establish an inventory of morphine use in emergency departments in the different centres studied.

Eligibility criteria:
inclusion criteria: all patients aged 18 years or older who require treatment with morphine for pain control will be considered for entry into the study. conscious without life threatening at the inclusion exclusion criteria: patients who receive morphine during or after an orotracheal intubation, altered level of consciousness, inability to give consent or refusal of patient.

Keywords: morphine adverse events predictive factors
use-results survey for orencia® subcutaneous injection 125mg syringe 1ml

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of orencia subcutaneous injection 125mg syringe 1ml in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * patients who are beginning to receive the treatment with orencia subcutaneous injection 125mg syringe 1ml under the approved indications, dosage, and administration
ventricular arrhythmias after pulmonary vein isolation

Conditions: Ventricular Arrhythmias; Atrial Fibrillation

Summary: the investigators study aimed to observe the occurrence of new premature ventricular complexes and other ventricular arrhythmias after pulmonary vein isolation.

atrial fibrillation is the most common arrhythmia with a lifetime risk for development of over 20%. pulmonary vein isolation is now established as therapy of choice for patients with symptomatic atrial fibrillation. it is well known that this interventional therapy inevitably modulates the intracardiac autonomic nervous system. while this ablation might alter atrial electrophysiology beneficially, the impact on ventricular electrophysiology remains unclear.

Eligibility criteria:
inclusion criteria: * age \> 18 years * paroxysmal atrial fibrillation scheduled to undergo pulmonary vein isolation exclusion criteria: * age \< 18 years * persistent atrial fibrillation * life expectancy less than 12 months * acute myocardial infarction, coronary artery bypass graft surgery, open heart surgery, or percutaneous transluminal coronary angioplasty within less than 3 months prior to inclusion * documentation of \>30 premature ventricular complexes per hour, salvos or ventricular tachycardias prior to atrial fibrillation ablation
a clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of nnc0114-0006 and liraglutide on preservation of beta-cell function

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted globally. the aim of this trial is to assess the clinical proof-of-principle of nnc0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * t1dm (type 1 diabetes mellitus) (as diagnosed clinically) for not more than 20 weeks prior to screening - male or female, aged 18-45 (both inclusive) at the time of signing the informed consent form * non-fasting peak c-peptide higher or equal to 0.2 nmol/l at visit 2 * bmi (body mass index) higher or equal to 18.5 kg/m\^2 * presence of one or more islet specific auto antibodies (glutamic acid decarboxylase (gad), islet antigen-2 (ia2) or zinc-transporter 8 (znt8)) at screening * insulin dependence unless in temporary spontaneous remission (honeymoon period) exclusion criteria: * daily insulin usage above 1 u/kg per day at screening or use of continuous subcutaneous insulin infusion (csii) * history of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic infections or conditions predisposing to chronic infections (e.g., bronchiectasis and chronic osteomyelitis) * history of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy * vaccination within 4 weeks before randomisation, visit 3 (v3) * receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening (v1) * history of pancreatitis (acute or chronic) * family or personal history of multiple endocrine neoplasia type 2 (men2) or medullary thyroid carcinoma (mtc) * any past or current diagnosis of malignant neoplasms * known impairment of the immune system, except for t1dm, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease), and vitiligo
clinical evaluation of the filmarray® global fever (gf) panel

Conditions: Fever

Summary: this study will evaluate the clinical sensitivity and specificity of the filmarray global fever (gf) panel.

the filmarray global fever (gf) panel, developed by biofire defense in collaboration with the u.s. department of defense and niaid, uses an automated, multiplex pcr system to evaluate whole blood samples for 19 pathogens simultaneously in under an hour. targets of the gf panel are chikungunya virus, cchf virus, dengue virus (serotypes 1-4), ebolavirus, lassa virus, marburgvirus, west nile virus, yellow fever virus, zika virus, bacillus anthracis, francisella tularensis, leptospira spp., salmonella enterica serovar typhi and paratyphi a, yersinia pestis, leishmania donovani complex, plasmodium spp., p. falciparum, and p. ovale/vivax. biofire defense is conducting a prospective clinical study to evaluate the sensitivity and specificity of the gf panel when used to test blood collected from subjects with fever or who have recently had fever. this multi-center study is being conducted at locations around the world.

Eligibility criteria:
inclusion criteria: * whole blood in edta (prospectively collected via informed consent) * subject has a recorded or self-reported fever within the past two days. * subject has not participated in the study within the last 30 days.
improving resection rates among african americans with nsclc

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: this is a randomized, interventional trial in which the navigation is the intervention. phase is not applicable. the study is a randomized trial to evaluate the impact of a nurse-led patient navigation intervention in improving rates of receipt of lung-directed therapy with curative intent (ldtci) among african americans with early stage lung cancer. study sites are cluster-randomized to either the usual care study arm or the to the navigation intervention study arm. randomization occurred at the level of the study site rather than at the level of individual participants. there are two arms.

the burden to participants will be minimized to enhance retention. patients in the usual care arm receive the current "gold standard" of treatment. the patients in the intervention arm are assigned to a pn, who helps to reduce the barriers to care that could negatively impact the patients' receipt of ldtci. the telephone-administered survey is administered to all study participants at baseline and at 3-, 6-, and 12-months post-enrollment. it takes approximately 30-40 minutes to administer. the telephone mode of survey administration was chosen to reduce the number of visits that would be required by each patient. interviews are scheduled at the convenience of the study participants. to further reduce burden to the study participants, the interviewers offer breaks during the interview process. patients in both arms undergo standard therapy visits. patients in the navigation arm receive standard therapy visits plus the navigation intervention. outside of the standard therapy visits, no additional clinic visits are required of the study participants. once informed consent has been obtained and the informed consent document is received, the ssc/pn will communicate to the musc hcc study staff the participant's contact information and that the participant is ready for baseline survey administration. all the study surveys will be administered by trained musc hcc study staff via telephone. a survey answer guide will be provided to the participant either in-person or via mail prior to administration of the baseline survey.

Eligibility criteria:
inclusion criteria: * aa race * clinically suspicious or biopsy-proven, early stage nsclc, and * ages 21 years and older exclusion criteria: * previous history of lung cancer * spread of newly diagnosed probably/proven lung cancer to other part of the body * diagnosis of synchronous cancer other than non-melanoma skin cancer or lung cancer, and * receipt of surgical resection or radiosurgery for lung cancer since diagnosis with probable/proven lung cancer

Keywords: non-small cell lung cancer (nsclc)
identification of breath biomarkers in esophageal cancer

Conditions: Esophageal Squamous Cell Carcinoma

Summary: neoadjuvant chemoradiotherapy (crt) followed by surgery or definitive crt is the standard treatment for locally advanced esophageal squamous cell carcinoma (escc), but the clinical outcomes are not satisfactory. breathomics testing is a promising, non-invasive, simple method for detection and screening for escc. this observational study aimed to role of exhaled volatile organic compounds (vocs) in predicting the efficacy and risk of recurrence in patients with locally advanced escc who received crt.

neoadjuvant chemoradiotherapy (crt) followed by surgery or definitive crt is the standard treatment for locally advanced esophageal squamous cell carcinoma (escc), but the clinical outcomes are not satisfactory. breathomics testing is a promising, non-invasive, simple method for detection and screening for escc. this observational study aimed to role of exhaled volatile organic compounds (vocs) in predicting the efficacy and risk of recurrence in patients with locally advanced escc who received crt. all patients will receive standard fractionation radiation therapy (rt) scheme: 40-50.4 gy in 20-28 fractions over 4-6 weeks using intensity-modulated radiotherapy, concurrently with platinum- or taxane-based chemotherapy, with or without pd-1 inhibitors. all patients will undergo esophagectomy 6-8 weeks after the completion of neoadjuvant crt. dynamic breathing testing was performed before, during, and after radiotherapy.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed squamous cell carcinoma of the esophagus; 2. absence of hematogenous metastasis disease, confirmed by endoscopic ultrasound (eus) and pet-ct scan (according to uicc tnm version 8); 3. age at diagnosis \>18 years; 4. no prior cancer therapy; 5. estimated life expectancy \>6 months; 6. eastern cooperative oncology group performance status ≤ 2 7. no history of concomitant or previous malignancy; 8. the function of important organs meets the following requirements: a. white blood cell count (wbc) ≥ 4.0×109/l, absolute neutrophil count (anc) ≥ 1.5×109/l; b. platelets ≥ 100×109/l; c. hemoglobin ≥ 9g/dl; d. serum albumin ≥ 2.8g/dl; e. total bilirubin ≤ 1.5×uln, alt, ast and/or akp ≤ 2.5×uln; f. serum creatinine ≤ 1.5×uln or creatinine clearance rate \>60 ml/min; 9. ability to understand the study and sign informed consent. exclusion criteria: 1. patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.); 2. patients with hematogenous metastasis disease at diagnosis; 3. female patients who are pregnant or lactating; 4. inability to provide informed consent due to psychological, familial, social and other factors; 5. patients who cannot tolerate chemoradiotherapy due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia. 6. the physical condition is not enough to provide 0.5l exhalation at one time.

Keywords: esophageal squamous cell carcinoma chemoradiotherapy dynamic breathomics testing
effectiveness of the cytokine hemadsorption on sepsis

Conditions: Interleukin-6

Summary: in this prospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in icu patients diagnosed with sepsis or septic shock.


Eligibility criteria:
inclusion criteria: * the patients were the available data of clinical and laboratory diagnosis of sepsis and septic shock * detection of gram-negative bacterial agent in blood or sputum culture. * patients who had the shock symptoms such as hypotension, tachycardia or fever during the course of sepsis. exclusion criteria: * had uncontrolled hemorrhage, * diagnosed with cardiac failure at stage 4 or renal failure at stage 4 or hepatic liver failure at stage 4 * cancer at the end stage or admitted with acute coronary syndrome.